DBV Technologies
29 rue du Faubourg
Saint Jacques
Paris
75014
France
Tel: 33-0-1-55-389270
Fax: 33-0-1-41-312882
Website: http://www.dbv-technologies.com/
Email: info@dbv-technologies.com
207 articles about DBV Technologies
-
DBV Tech Announces Completion Of Blinded Period In REALISE Study Of Viaskin Peanut
10/12/2017
-
DBV Tech Initiates Phase III Study Of Viaskin Peanut In Peanut-Allergic Patients One To Three Years Of Age
8/2/2017
-
Half-Year Report On The DBV Tech Liquidity Contract With Natixis
7/6/2017
-
DBV Tech Announces Results Of Its 2017 Ordinary And Extraordinary General Meeting
6/16/2017
-
DBV Tech Announces Appointment Of Julie O'Neill To Board Of Directors
6/16/2017
-
DBV Tech To Attend Upcoming Investor Conferences
6/2/2017
-
DBV Tech Highlights Research Presentation Of EPIT For The Treatment Of Crohn's Disease At Digestive Disease Week 2017
5/8/2017
-
DBV Tech Reports March 31, 2017 Cash Position
4/28/2017
-
DBV Tech To Attend The 10th Kempen Life Sciences Conference
4/5/2017
-
DBV Tech, BioNet-Asia And Geneva University Hospitals Announce Phase I Trial Results Of Viaskin rPT In Pertussis Booster Vaccination
3/31/2017
-
DBV Tech Announces Filing Of Its 2016 "Document De Référence" And Annual Report On Form 20-F
3/23/2017
-
DBV Tech Reports Full Year 2016 Financial Results
3/15/2017
-
DBV Tech Announces Completion Of Enrollment Of The REALISE Study In Peanut Allergic Children
3/10/2017
-
DBV Tech Release: Data At AAAAI 2017 Show Lasting Response And Favorable Safety Profile Of Investigational Agent, Viaskin Peanut, Throughout Three Years Of Treatment Of Peanut Allergic Children
3/6/2017
-
DBV Tech To Attend Upcoming Investor Conferences
3/1/2017
-
DBV Tech To Present Data At The 2017 AAAAI Meeting Highlighting The Therapeutic Potential Of EPIT
2/13/2017
-
DBV Tech Announces Completion Of Enrollment Of Phase IIA Study Of Viaskin Milk For The Treatment Of Pediatric Eosinophilic Esophagitis
2/3/2017
-
DBV Tech Announces Financial Calendar 2017
1/9/2017
-
DBV Tech, BioNet-Asia And Geneva University Hospitals Complete Dosing In First Cohort Of Phase I Study Of Viaskin Rpt For Booster Vaccination Against Pertussis
11/17/2016
-
DBV Tech Completes Enrollment Of Phase II Study Of Viaskin Milk For The Treatment Of Milk Allergic Patients
11/8/2016